Baidu
map

相约首都:重症医学液体复苏研讨会重磅来袭!

2019-04-04 小M MedSci原创

重磅学术会议“重症医学液体复苏研讨会”将于2019年4月14日上午在北京召开。

随着重症医学的迅速发展,医学界在急危重症患者的抢救和延续性生命支持策略方面取得了很大的进步。作为重要治疗手段,液体复苏策略始终是重症学科医生们密切关注的临床问题。

为了进一步促进重症医学领域的发展,探索液体复苏策略,重磅学术会议“重症医学液体复苏研讨会”将于2019年4月14日上午在北京召开。届时,多位具有丰富临床经验的重症医学领域“大咖”将齐聚一堂,除了三场干货满满的讲座,会议还设置了热火朝天的讨论环节,着重分析探讨“脓毒症液体复苏策略”、“最佳复苏液体,是否存在?”和“创伤失血液体复苏策略”几个话题。

脓毒症液体复苏策略

脓毒症是ICU一大“杀手”,开始积极的液体复苏和建立血管通路是管理脓毒症或严重脓毒性休克患者的首要目标。如何制定4D和4个阶段的治疗策略?EGDT,过时了吗?限制性液体复苏是脓毒血症低血容量的解决之道吗?本次研讨会将结合脓毒症液体复苏的最新临床现状和治疗策略探索最适宜的脓毒症液体复苏策略,为听众在脓毒症的临床治疗中提供帮助。

最佳复苏液体,是否存在?

“补液”是重症监护病房非常基本与常见的治疗。面对形形色色的复苏液体,临床医生的最佳选择是什么?各种晶体、人工胶体和天然胶体的区别分别是什么?本次研讨会将带来国内外关于这些问题的最新信息与专家见解,相信一定能让听众有所收获。

创伤失血液体复苏策略

创伤是人类医学史最古老的研究课题之一,也是现代医学的重要领域。由于社会的进步和医学的发展,一些疾病(如许多传染病)已得到有效的控制,但创伤却有增无减。近年发生的几起触目惊心的公共安全事件,更是提醒广大急危重症医师时刻保持对创伤的关注。分秒必争的情况下,如何制定最有效的创伤失血液体复苏策略守护患者的生命?本次研讨会中,各位专家学者带来自己宝贵的临床经验,为听众制定创伤失血液体复苏策略提供参考。

会议亮点

群英荟萃:多位权威专家齐聚一堂

本次会议,我们荣幸地邀请到了在国内重症医学领域具有广泛学术声誉的专家——安友仲教授作为主席。

安友仲,主任医师,教 授。

中华医学会重症医学分会常委、北大人民医院重症医学科科主任。

报告专家有:

张西京,主任医师,教 授。

中国医师协会重症医学医师分会常委、空军军医大学西京医院ICU中心主任。

徐磊,主任医师,教 授。

中华医学会重症医学分会常务委员、天津市第三中心医院重症医学科主任。

邵换璋,主任医师,教 授。

中华医学会重症医学分会青年委员、河南省人民医院急危重症医学部副主任。

畅所欲言:主题讨论精彩纷呈

报告之后,会议全体将进行主题讨论。届时,具有丰富研究基础和临床经验的各位专家学者将通过讨论分享自己在重症医学领域的宝贵经验。

更多精彩,请关注后续报道!

会议时间

2019年4月14日(周日)

会议地点

北京金都假日酒店(西城区北礼士路98号)

会议日程


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994824, encodeId=99de199482429, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 06 01:04:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305470, encodeId=0dce13054e088, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549464, encodeId=46e615494640a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556955, encodeId=bbcb1556955ad, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579623, encodeId=0a2915e9623ee, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-08-06 kcb069
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994824, encodeId=99de199482429, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 06 01:04:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305470, encodeId=0dce13054e088, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549464, encodeId=46e615494640a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556955, encodeId=bbcb1556955ad, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579623, encodeId=0a2915e9623ee, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 lizhou0204
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994824, encodeId=99de199482429, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 06 01:04:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305470, encodeId=0dce13054e088, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549464, encodeId=46e615494640a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556955, encodeId=bbcb1556955ad, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579623, encodeId=0a2915e9623ee, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 xxxx1054
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994824, encodeId=99de199482429, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 06 01:04:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305470, encodeId=0dce13054e088, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549464, encodeId=46e615494640a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556955, encodeId=bbcb1556955ad, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579623, encodeId=0a2915e9623ee, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1994824, encodeId=99de199482429, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 06 01:04:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305470, encodeId=0dce13054e088, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549464, encodeId=46e615494640a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556955, encodeId=bbcb1556955ad, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579623, encodeId=0a2915e9623ee, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sat Apr 06 08:04:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map